Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$35.01 USD

35.01
162,393

-0.02 (-0.06%)

Updated Aug 7, 2025 03:59 PM ET

After-Market: $35.02 +0.01 (0.03%) 7:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hologic (HOLX) Posts Q2 Preliminary Results, Withdraws View

by Zacks Equity Research

Investors remain optimistic with Hologic's (HOLX) balanced segmental preliminary revenue results for second-quarter fiscal 2020.

Zacks Equity Research

Here's Why You Should Add Surmodics to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high in Surmodics' (SRDX) stock,thanks to solid prospects.

Zacks Equity Research

SurModics (SRDX) Down 22.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Zacks Equity Research

SurModics (SRDX) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 266.67% and -0.89%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline

by Zacks Equity Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline

by Zacks Equity Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.

Zacks Equity Research

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.

Zacks Equity Research

Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.

Zacks Equity Research

SurModics (SRDX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 5.71% and 8.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LabCorp (LH) Q3 Earnings Surpass Estimates, Tapers View

by Zacks Equity Research

LabCorp (LH) impresses investors with third-quarter 2019 results on the robust performance of the Covance Drug Development segment.

Zacks Equity Research

Here's Why You Should Hold on to Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Abbott's (ABT) performance.

Zacks Equity Research

ResMed Upgrades Nasal Care by Introducing Cradle CPAP Mask

by Zacks Equity Research

ResMed (RMD) revolutionizes sleep apnea treatment by introducing a hassle-free and easy-to-use mask.

Trina Mukherjee headshot

Medical Products Industry Outlook: Prospects Seem Promising

by Trina Mukherjee

Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.

Zacks Equity Research

Here's Why You Should Hold on to Chemed (CHE) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed's (CHE) performance.

Zacks Equity Research

Organigram (OGI) Catches Eye: Stock Jumps 8.6%

by Zacks Equity Research

Organigram (OGI) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Zacks Equity Research

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for September 26th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 26th

Zacks Equity Research

Will SurModics (SRDX) Gain on Rising Earnings Estimates?

by Zacks Equity Research

SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Nalak Das headshot

Wall Street Bulls Roaring Despite Slowdown Fears: 5 Top Picks

by Nalak Das

Year to date, the performance on Wall Street is projecting a glorious picture with no end to the bull run in sight, at least this year.

Zacks Equity Research

Stryker's Mobius Imaging Buyout to Boost Its Spine Division

by Zacks Equity Research

Stryker (SYK) expects the buyout to remain neutral to its 2019 earnings.

Zacks Equity Research

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Zacks Equity Research

Haemonetics (HAE) Beats on Q1 Earnings, Raises '19 EPS View

by Zacks Equity Research

Haemonetics (HAE) Q1 performance by all business sections has been impressive, except for BloodCenter.

Zacks Equity Research

BioScrip Closes Option Care Merger, Incurs Wider Q2 Loss

by Zacks Equity Research

With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.